The global TMJ Disorder Market is expected to register a healthy market growth owing to the increase in technological advancement and increasing prevalence of these disorders. The emergence of non-surgical and surgical treatment methods for TMJ disorders is expected to drive market growth during the review period. TMJ disorders are the second-most commonly occurring musculoskeletal conditions resulting in pain and disability. The occurrences of TMD peaks from the age of 20-40 years, and it is found to be more prevalent in women than men. Additionally, women who use supplemental estrogenic or oral contraceptives are more expected to seek treatment for these conditions. Therefore, the increasing prevalence of these disorders in these populations is further fuelling the market growth during the review period.
Market Segmentation
The Global TMJ Disorders Market has been classified into Type, treatment, and end-user.
Based on type segment, the Global TMJ Disorders Market, based on Type classified into myofascial Pain, Internal Derangement (ID), and Osteoarthritis.
In terms of treatment, the market has been divided into medication, therapies, surgical, and others. The medication segment is further sub-divided into pain relievers, anti-inflammatories, tricyclic antidepressants, muscle relaxants, and others.
Based on end-user, the global TMJ disorders market is segmented into hospitals and clinics, ambulatory surgery centers, academic institutes, and others.
Regional Analysis
Geographically, the Global TMJ Disorder Market has been classified into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas market has been divided into North America and Latin America, with the North America market further segmented into the US and Canada. The Americas is expected to dominate the global market owing to the largest share of 49.20% of the TMJ disorder market in 2019. This largest share is driven by the introduction and rapid adoption of advanced treatments in the region.
The European TMJ disorder market has been bifurcated into Western Europe and Eastern Europe. The Western Europe TMJ disorder market has further been divided into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. The TMJ disorder market in Asia-Pacific has been classified into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. The Middle East & Africa TMJ disorder market has been segmented into the Middle East and Africa.
Major Players
The key players in the global TMJ Disorders market are Abbott Laboratories, Sun Pharmaceutical Industries Limited, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Allergan, Bayer AG, Zydus Cadila, Mylan NV, Novartis International AG, and Jubilant Life Sciences Limited.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

The post Global TMJ Disorders Market Research Report—Forecast till 2027 first appeared on CRI Report.

Market Overview
Global Urinary Tract Infections Market is anticipated to exhibit a CAGR of 3.62% during the review period of 2020 to 2027. The infection in urinary system parts such as kidneys, ureters, bladder, and urethra are referred to as urinary tract infection. The major causes of UTI infection are unsafe sex, lack of hygiene, and diabetes.
Global Urinary Tract Infections Market is expected to register the highest market growth owing to the largest market value of USD 9,490.88 Million in 2019. As per the World Health Organization, 1 million hospitalizations of women occur each year due to UTIs, which affect almost half the female population around the world. Urological health issues are more common in diabetic patients. An increasing prevalence of diabetic population is expected to boost the global UTI patients worldwide. However, complex regulatory requirements are anticipated to restrain the growth of the global urinary tract infection market during the review period.
Market Segmentation
Global Urinary Tract Infections Market has been segmented into Drug Class, Application, Pathogen, End User.
In terms of drug class, the market has been classified into quinolones, β-lactam & cephalosporins, aminoglycosides, penicillin, and azoles. The quinolones segment is further sub-divided into ciprofloxacin, enoxacin, norfloxacin, ofloxacin, pefloxacin, and fleroxacin. The cephalosporin is again classified into avycaz, cedax, cefdinir, and cefditoren. The β-lactam is further divided into amoxicillin-clavulanate, cefdinir, cefaclor, and cefpodoxime-proxetil.
The Global Urinary Tract Infections Market, based on application, has been divided into urethritis, cystitis, and pyelonephritis. In terms of the pathogen, the market has been categorized into Escherichia coli, Staphylococcus saprophyticus, Klebsiella pneumoniae, Proteus mirabilis, and Enterococcus faecalis. By end-user category, the global urinary tract infections market has been classified into hospitals, clinics, self-administered, and others.
Regional Analysis
Geographically, the global UTI market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to dominate the global market owing to the largest market share of 33.6% of the global market in 2019. The regional market growth is driven by the presence of key manufacturers, the increasing prevalence of urinary tract infections, and the increasing aging woman population in the region. The market in the Americas is categorized into North America and Latin America. Additionally, the global market growth is driven by the increasing technological advancements in diagnostics and therapeutic products coupled with the rising prevalence of urinary tract diseases and other kidney problems.
Europe is expected to register the second-largest market of the Global Urinary Tract Infection. The regional market is segmented into France, Germany, Italy, Spain, and the UK. The regional market growth is attributed to the increasing awareness of urinary tract diseases, increasing educational activity, and the availability of different diagnostic and therapeutic methods to manage the infection. Asia-Pacific is set to exhibit the fastest-growing market for UTI during the review period. The regional market growth is driven by the developing economies and highly populated countries such as China, India, and South Korea.
Major Players
The Prominent Players in the Global Urinary Tract Infections Market are Pfizer Inc., Novo Nordisk A/S, Novartis Ag, Merck & Co., Inc., Eli Lily and Company, Allergan, Cipla Inc., Teva Pharmaceuticals, GlaxoSmithKline plc, and Bayer AG.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

The post Urinary Tract Infection Market Research Report—Forecast till 2027 first appeared on CRI Report.